Mitochondrial neurogastrointestinal encephalopathy syndrome
(Redirected from Mitochondrial neurogastrointestinal encephalomyopathy)
Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE syndrome) is a rare, autosomal recessive mitochondrial disorder that affects the gastrointestinal tract and the nervous system. It is characterized by a combination of gastrointestinal dysmotility, peripheral neuropathy, leukoencephalopathy, and ptosis.
Signs and Symptoms[edit | edit source]
Individuals with MNGIE syndrome typically present with a variety of symptoms, including:
- Severe gastrointestinal dysmotility leading to chronic diarrhea, vomiting, and abdominal pain
- Peripheral neuropathy causing muscle weakness and sensory disturbances
- Leukoencephalopathy which can be detected through magnetic resonance imaging (MRI)
- Ptosis and ophthalmoplegia
- Cachexia and severe weight loss
Genetics[edit | edit source]
MNGIE syndrome is caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase. This enzyme is crucial for the proper maintenance of mitochondrial DNA. Mutations in the TYMP gene lead to the accumulation of thymidine and deoxyuridine, which are toxic to mitochondria and result in mitochondrial dysfunction.
Diagnosis[edit | edit source]
The diagnosis of MNGIE syndrome is based on clinical evaluation, family history, and genetic testing. Elevated levels of thymidine and deoxyuridine in the blood and urine are indicative of the disorder. Magnetic resonance imaging (MRI) of the brain may show characteristic changes associated with leukoencephalopathy.
Treatment[edit | edit source]
There is currently no cure for MNGIE syndrome. Treatment is primarily supportive and focuses on managing symptoms. This may include:
- Nutritional support to address gastrointestinal symptoms and prevent malnutrition
- Medications to manage gastrointestinal motility
- Physical therapy to address muscle weakness and peripheral neuropathy
Prognosis[edit | edit source]
The prognosis for individuals with MNGIE syndrome is generally poor, with most patients experiencing a progressive decline in health. The disorder often leads to severe disability and can be life-threatening.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD